ANIP ANI Pharmaceuticals Inc.

ANI Pharmaceuticals to Present at the Leerink Partners Global Biopharma Conference

ANI Pharmaceuticals to Present at the Leerink Partners Global Biopharma Conference

BAUDETTE, Minn., Feb. 20, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that Nikhil Lalwani, Chief Executive Officer, and Stephen Carey, Chief Financial Officer, will present at the Leerink Partners Global Biopharma Conference in Miami Beach as follows:

Date: Tuesday, March 12, 2024
   
Time: 2:20 p.m. ET
   
Webcast: 
   

To schedule a 1x1 meeting with the Company, please contact your Leerink representative.

The live and archived webcast will be accessible from the Company’s website at , under the Investors section under Events and Presentations. The replay of the webcast will be accessible for 90 days.

About ANI

ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) is a diversified biopharmaceutical company serving patients in need by developing, manufacturing, and marketing high quality branded and generic prescription pharmaceutical products, including for diseases with high unmet medical need. Our team is focused on delivering sustainable growth by scaling up our Rare Disease business through the successful launch of our lead asset, Purified Cortrophin® Gel, strengthening our generics business with enhanced research and development capability, innovation in established brands and leveraging our North American manufacturing capabilities. For more information, please visit our website .

Investor Relations:

Lisa M. Wilson, In-Site Communications, Inc.

T: 212-452-2793

E:

Source: ANI Pharmaceuticals, Inc.



EN
20/02/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ANI Pharmaceuticals Inc.

 PRESS RELEASE

ANI Pharmaceuticals Announces the FDA Approval and Launch of Ketoconaz...

ANI Pharmaceuticals Announces the FDA Approval and Launch of Ketoconazole Shampoo, 2% PRINCETON, N.J., Sept. 26, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that following final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA), the Company launched Ketoconazole Shampoo, 2%. ANI’s Ketoconazole Shampoo, 2% is the generic version of the reference listed drug (RLD) Nizoral®. "We are proud to announce the FDA approval and commercialization of Ketoconazole Shampoo, 2%, another li...

 PRESS RELEASE

ANI Pharmaceuticals, Inc. Completes Acquisition of Alimera Sciences

ANI Pharmaceuticals, Inc. Completes Acquisition of Alimera Sciences Strengthens Rare Disease segment as largest driver of future growth, adding approximately $105 million in 2024 revenue on a pro forma basisAdds two durable commercial assets ILUVIEN® and YUTIQ® with significant growth potential, expanding ANI’s foothold in strategic therapeutic area of ophthalmologyAnticipated to drive high single-digit to low double-digit accretion in adjusted non-GAAP EPS in 2025 and to be substantially accretive thereafterNew capital structure in place, reducing interest expense by approximately $39 mill...

 PRESS RELEASE

ANI Pharmaceuticals Initiates Closing of Acquisition of Alimera Scienc...

ANI Pharmaceuticals Initiates Closing of Acquisition of Alimera Sciences PRINCETON, N.J., Sept. 16, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (“ANI” or the “Company”) announced today that the Company has initiated closing logistics for the previously announced acquisition of Alimera Sciences, Inc. (Nasdaq: ALIM). The Company expects closing of the acquisition of Alimera Sciences to be consummated and announced today, pending satisfaction or waiver of any remaining customary closing conditions. About ANI Pharmaceuticals, Inc. ANI Pharmaceuticals, Inc. (Nasdaq: AN...

 PRESS RELEASE

ANI Pharmaceuticals Launches Promethazine Hydrochloride and Dextrometh...

ANI Pharmaceuticals Launches Promethazine Hydrochloride and Dextromethorphan Hydrobromide Oral Solution PRINCETON, N.J., Sept. 13, 2024 (GLOBE NEWSWIRE) --  ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced the launch of Promethazine Hydrochloride and Dextromethorphan Hydrobromide Oral Solution, 6.25 mg/15 mg per 5 mL. "The launch of Promethazine Hydrochloride and Dextromethorphan Hydrobromide Oral Solution just prior to the onset of cough and cold season is especially timely. With our 14th new product launch this year, we continue to drive strong growth in ou...

 PRESS RELEASE

ANI Pharmaceuticals and Alimera Sciences Announce Closing Date of Merg...

ANI Pharmaceuticals and Alimera Sciences Announce Closing Date of Merger ANI and Alimera Scheduled the Closing for September 16, 2024 PRINCETON, N.J. and ATLANTA, Sept. 11, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) (“ANI”) and Alimera Sciences, Inc. (NASDAQ: ALIM) (“Alimera” or the “Company”) today jointly announced that they have scheduled the closing of their transaction pursuant to the companies’ previously announced Merger Agreement for before the market opens on Monday, September 16, 2024. About ANI Pharmaceuticals, Inc.ANI Pharmaceuticals, Inc. ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch